Form 4: Pfizer Executive Vice President Douglas Lankler Reports Stock Transactions

Executive Vice President Douglas M. Lankler reports the earn-out of stock appreciation rights and related transactions involving Pfizer Inc. common stock.

Summary

• Douglas M. Lankler, an Executive Vice President at Pfizer Inc., reported transactions involving the company's common stock on February 27, 2025.
• These transactions included the earn-out of 156,914 stock appreciation rights at a price of $31.31.
• Lankler also disposed of 3,589 shares to satisfy tax obligations at $26.1 per share and 146,961 shares to cover the exercise price of the stock appreciation rights at $26.06 per share.
• Following these transactions, Lankler directly owns 159,240 shares of Pfizer common stock and indirectly owns 1,951 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a normal part of compensation and wealth management in publicly traded companies like Pfizer.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies such as Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV).
• The reporting requirements are standardized under SEC regulations, ensuring transparency across the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the executive's holdings.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates